demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
anticoagulant, curative dose COALIZAO ACTION ATTACC, ACTIV-4a, and REMAP-CAP ... COVID-PACT REMAP-CAP, ACTIV-4a, ATTACC ...

2 studies excluded by filtering options 0

5777 Bousquet, 2020 1130not a RCTrisk of bias not avaialble
10523 FREEDOM COVID, 2023 010selection pending